|
2.11 ETIOLOGIE - ALIMENTATION
|
|
|
|
3. PRÉVENTION
|
|
|
The Cancer Miracle Isn’t a Cure. It's Prevention. [Harvard Public Health]
|
|
|
|
|
|
There are many reasons why prevention research is unenticing. Most societies are reactive, not proactive. The final phases of research on treatment are simpler than research on prevention. Curing a patient with advanced disease is more dramatic than preventing disease in a healthy person. And perhaps most conspicuously, treatments earn far higher profits than do new diagnostics or prevention measures.
|
|
|
|
|
|
|
3.1.1 PRÉVENTION - TABAC - E-CIGS
|
|
|
How safe are e-cigarettes? [Imperial College London]
|
|
|
|
|
|
“I think it’s fair to say that if you use a product from a reputable source to vape, then it’s going to be a lot less harmful to you, than if you were to use conventional cigarettes. By ‘a lot less harmful’, I can’t put a definite number on it, but I would say between probably no less than 90-95 per cent less harmful.”
|
|
|
|
|
|
|
|
Nicotine sickness: the latest vaping scare [The Guardian]
|
|
|
|
|
|
One major problem is trying to convince addicted teenagers to actually commit to quitting nicotine in the first place. But unless this happens, science suggests that many of these vapers will ultimately end up using both e-cigarettes and cigarettes, with potentially grave health consequences.
|
|
|
|
|
|
|
4.1 DÉP., DIAG. & PRONO. - PROSTATE
|
|
|
Understanding PSA testing: A Q&A [Stanford]
|
|
|
|
|
|
Issue number one is getting false positives -- and that happens a lot. For men with a high PSA, in the 4 ng/mL to 10 ng/mL range, we find cancer in about 25% of cases when we do a biopsy. That means there are a whole lot of guys who got a biopsy of their prostate that didn't need to.
|
|
|
|
|
|
|
4.9 DÉP., DIAG. & PRONO. - SEIN
|
|
|
|
5. TRAITEMENTS
|
|
|
|
5.10 TRAITEMENTS - ESSAIS
|
|
|
|
Calculating the Costs of Clinical Trials [ASH]
|
|
|
|
|
|
ASH Clinical News recently spoke with several clinical trial and ethics experts about the hidden costs of clinical trial participation, the prices of post-trial access to investigational drugs, and some of the steps being taken to ease this burden.
|
|
|
|
|
|
|
6. LUTTE CONTRE LES CANCERS
|
|
|